Lyell Immunopharma (LYEL) Stock Forecast & Price Target

$0.68 +0.06 (+10.18%)

(As of 02:57 PM ET)

Lyell Immunopharma - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Reduce

Based on 2 Analyst Ratings

Sell
1

Hold
1

Buy
0

Based on 2 Wall Street analysts who have issued ratings for Lyell Immunopharma in the last 12 months, the stock has a consensus rating of "Reduce." Out of the 2 analysts, 1 has given a sell rating, and 1 has given a hold rating for LYEL.

Consensus Price Target

$1.00
48.08% Upside

According to the 2 analysts' twelve-month price targets for Lyell Immunopharma, the average price target is $1.00. The highest price target for LYEL is $1.00, while the lowest price target for LYEL is $1.00. The average price target represents a forecasted upside of 48.08% from the current price of $0.68.

Get the Latest News and Ratings for LYEL and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Lyell Immunopharma and its competitors.

LYEL Analyst Ratings Over Time

Type	Current Forecast 12/27/23 to 12/26/24	1 Month Ago 11/27/23 to 11/26/24	3 Months Ago 9/28/23 to 9/27/24	1 Year Ago 12/27/22 to 12/27/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	0 Buy rating(s)	0 Buy rating(s)	1 Buy rating(s)	1 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	2 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$1.00	$1.00	$3.50	$5.67
Forecasted Upside	48.08% Upside	8.26% Upside	131.79% Upside	168.56% Upside
Consensus Rating	Reduce	Reduce	Moderate Buy	Hold

Has Trump Finally Gone Too Far? (Ad)

Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.

LYEL Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

LYEL Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Lyell Immunopharma Stock vs. The Competition

Type	Lyell Immunopharma	Medical Companies	S&P 500
Consensus Rating Score	1.50	2.81	2.51
Consensus Rating	Reduce	Moderate Buy	Moderate Buy
Predicted Upside	63.16% Upside	26,168.89% Upside	13.49% Upside
News Sentiment Rating	Neutral News See Recent LYEL News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/12/2024	HC Wainwright 2 of 5 stars	M. Kapoor Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$1.00 ➝ $1.00	-17.36%
10/30/2024	Bank of America 3 of 5 stars		Downgrade	Buy ➝ Underperform	$6.00 ➝ $1.00	+5.47%
8/28/2023	JPMorgan Chase & Co. 3 of 5 stars		Downgrade	Overweight ➝ Neutral	$15.00 ➝ $5.00	+118.34%
1/24/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight	$7.00 ➝ $4.00	+34.23%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 03:13 PM ET.

LYEL Forecast - Frequently Asked Questions

: According to the research reports of 2 Wall Street equities research analysts, the average twelve-month stock price forecast for Lyell Immunopharma is $1.00, with a high forecast of $1.00 and a low forecast of $1.00.
: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lyell Immunopharma in the last twelve months. There is currently 1 sell rating and 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "reduce" LYEL shares.
: According to analysts, Lyell Immunopharma's stock has a predicted upside of 48.08% based on their 12-month stock forecasts.
: Over the previous 90 days, Lyell Immunopharma's stock had 1 downgrade by analysts.
: Lyell Immunopharma has been rated by research analysts at Bank of America, and HC Wainwright in the past 90 days.
: Analysts like Lyell Immunopharma less than other "medical" companies. The consensus rating for Lyell Immunopharma is Reduce while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how LYEL compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

[PDF] The Opportunity in Gold (Ad)

Commodities expert, Geof Smith, insists that the supercycle on gold is just getting warmed up. In fact, even though gold looks like this since he initially called a major bull run 11 months ago… He’s still predicting it will be the TOP trade of 2025. His free eBook explains why You see, the last time gold launched into a supercycle like this it surged 536% The time before that was over 1,000%... That’s why Geof released this urgent guide to help you. Most people think they’ve missed out, but he thinks we’re at the very beginning of what could be the largest gold rally of our lifetimes. But, believe it or not, Geof doesn’t think you should just buy and hold precious metals. He’ll share more about his approach inside the eBook and it might surprise you.

Tap here to read it

This page (NASDAQ:LYEL) was last updated on 12/26/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lyell Immunopharma (LYEL) Stock Forecast & Price Target